12:00 AM
 | 
Dec 09, 2013
 |  BC Week In Review  |  Company News  |  Other News

Auspherix infectious news

Auspherix debuted with A$1 million ($914,700) in seed funding from Australia's Medical Research Commercialization Fund (MRCF) to develop antibiotics to treat resistant bacterial diseases. The newco will in-license IP from the...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >